Therapy Areas: Oncology
XNK Therapeutics names new director
10 May 2022 -

XNK Therapeutics AB (XNK), a Sweden-based clinical stage, immunotherapy company, announced on Monday that it has named Ted Fjallman as its new director.

Fjallman is a Partner at Flerie Invest. He has served as the CEO and board member of various biotech companies engaged in a wide range of areas including immunology, oncology and biologics development and manufacturing.

XNK's chairman of the board, Gunnar Mattsson, said, 'We are very happy to welcome Ted Fjällman as new board member. With his solid life science background, he will add valuable expertise and experience to the board.'

Login
Username:

Password:


Related Headlines